Cargando…
Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
Andexanet alfa is an analog of activated factor X and is used as an antagonist of anti-activated factor X agents. Andexanet alfa is useful for hemostasis in emergent bleeding during direct oral anticoagulant administration, which contributes to safety. In patients undergoing surgery with cardiopulmo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516723/ https://www.ncbi.nlm.nih.gov/pubmed/37746371 http://dx.doi.org/10.7759/cureus.44003 |
_version_ | 1785109187464790016 |
---|---|
author | Kitaura, Atsuhiro Iwamoto, Tatsushige Hamasaki, Shinichi Tsukimoto, Shota Nakajima, Yasufumi |
author_facet | Kitaura, Atsuhiro Iwamoto, Tatsushige Hamasaki, Shinichi Tsukimoto, Shota Nakajima, Yasufumi |
author_sort | Kitaura, Atsuhiro |
collection | PubMed |
description | Andexanet alfa is an analog of activated factor X and is used as an antagonist of anti-activated factor X agents. Andexanet alfa is useful for hemostasis in emergent bleeding during direct oral anticoagulant administration, which contributes to safety. In patients undergoing surgery with cardiopulmonary bypass because of heparin resistance, anesthesiologists are faced with a choice of anticoagulants. Herein, we experienced anesthesia for vascular prostheses with cardiopulmonary bypass for acute aortic dissection in a patient who had received andexanet alfa preoperatively. Heparin was initially used as the anticoagulant during cardiopulmonary bypass; however, despite the administration of large doses and antithrombin III preparations, anticoagulation was insufficient. Therefore, nafamostat mesilate was administered and sufficient anticoagulation was attained. The patient completed surgery under cardiopulmonary bypass, coagulation function was recovered shortly after withdrawal, and no obvious adverse effects were observed. |
format | Online Article Text |
id | pubmed-10516723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-105167232023-09-24 Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance Kitaura, Atsuhiro Iwamoto, Tatsushige Hamasaki, Shinichi Tsukimoto, Shota Nakajima, Yasufumi Cureus Anesthesiology Andexanet alfa is an analog of activated factor X and is used as an antagonist of anti-activated factor X agents. Andexanet alfa is useful for hemostasis in emergent bleeding during direct oral anticoagulant administration, which contributes to safety. In patients undergoing surgery with cardiopulmonary bypass because of heparin resistance, anesthesiologists are faced with a choice of anticoagulants. Herein, we experienced anesthesia for vascular prostheses with cardiopulmonary bypass for acute aortic dissection in a patient who had received andexanet alfa preoperatively. Heparin was initially used as the anticoagulant during cardiopulmonary bypass; however, despite the administration of large doses and antithrombin III preparations, anticoagulation was insufficient. Therefore, nafamostat mesilate was administered and sufficient anticoagulation was attained. The patient completed surgery under cardiopulmonary bypass, coagulation function was recovered shortly after withdrawal, and no obvious adverse effects were observed. Cureus 2023-08-23 /pmc/articles/PMC10516723/ /pubmed/37746371 http://dx.doi.org/10.7759/cureus.44003 Text en Copyright © 2023, Kitaura et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Anesthesiology Kitaura, Atsuhiro Iwamoto, Tatsushige Hamasaki, Shinichi Tsukimoto, Shota Nakajima, Yasufumi Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance |
title | Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance |
title_full | Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance |
title_fullStr | Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance |
title_full_unstemmed | Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance |
title_short | Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance |
title_sort | successful nafamostat mesilate administration for andexanet alfa-induced heparin resistance |
topic | Anesthesiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516723/ https://www.ncbi.nlm.nih.gov/pubmed/37746371 http://dx.doi.org/10.7759/cureus.44003 |
work_keys_str_mv | AT kitauraatsuhiro successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance AT iwamototatsushige successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance AT hamasakishinichi successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance AT tsukimotoshota successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance AT nakajimayasufumi successfulnafamostatmesilateadministrationforandexanetalfainducedheparinresistance |